Efficacy of fixed-dose combination tablets with candesartan 8 mg/hydrochlorothiazide 6.25 mg and candesartan 8 mg/amlodipine 5 mg in Japanese patients with hypertension

Toshiki Wakabayashi, Yoshifumi Saisho, Toshihide Kawai, Kohichi Hayashi, Hiroshi Itoh

Research output: Contribution to journalArticle

Abstract

Aims: To examine efficacy of fixed-dose combination tablets with candesartan 8 mg/hydrochlorothiazide 6.25 mg (ARB/DU) and candesartan 8 mg/amlodipine 5 mg (ARB/CCB) in Japanese patients with hypertension. Methods: We conducted a retrospective analysis of 201 Japanese patients with hypertension who were treated with ARB/DU (n = 92) or ARB/CCB (n = 102) for 1 year. We examined change in blood pressure control as well as other clinical parameters. Correlations between change in blood pressure and clinical parameters were also determined. Results: After switching ARB/DU or ARB/CCB, systolic (SBP) and diastolic blood pressure (DBP) was significantly decreased in the both groups (Δ SBP: 8.1 and 8.5 mmHg and Δ DBP: 3.7 and 4.3 mmHg, respectively, all p < 0.01). Number of antihypertensives was significantly decreased after switching (3.0 ± 1.9 → 2.3 ± 1.4 tablets, p = 0.01 and 2.5 ± 1.6 → 1.3 ± 0.7 tablets, p < 0.01, respectively). There was a significant negative correlation between change in blood pressure after switching and blood pressure at baseline (p < 0.01). Conclusion: In clinical settings, use of fixed-dose combination tablets of ARB/DU and ARB/CCB significantly improved blood pressure control in Japanese patients with hypertension. Especially, switching to fixed-dose combination tablet should be considered in patients with poor blood pressure control.

Original languageEnglish
Pages (from-to)1111-1118
Number of pages8
JournalTherapeutic Research
Volume34
Issue number8
Publication statusPublished - 2013

Fingerprint

Amlodipine
Hydrochlorothiazide
Tablets
Blood Pressure
Hypertension
candesartan
Antihypertensive Agents

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy of fixed-dose combination tablets with candesartan 8 mg/hydrochlorothiazide 6.25 mg and candesartan 8 mg/amlodipine 5 mg in Japanese patients with hypertension. / Wakabayashi, Toshiki; Saisho, Yoshifumi; Kawai, Toshihide; Hayashi, Kohichi; Itoh, Hiroshi.

In: Therapeutic Research, Vol. 34, No. 8, 2013, p. 1111-1118.

Research output: Contribution to journalArticle

@article{d0af35cc4cf341e9a44edb1cf2f15170,
title = "Efficacy of fixed-dose combination tablets with candesartan 8 mg/hydrochlorothiazide 6.25 mg and candesartan 8 mg/amlodipine 5 mg in Japanese patients with hypertension",
abstract = "Aims: To examine efficacy of fixed-dose combination tablets with candesartan 8 mg/hydrochlorothiazide 6.25 mg (ARB/DU) and candesartan 8 mg/amlodipine 5 mg (ARB/CCB) in Japanese patients with hypertension. Methods: We conducted a retrospective analysis of 201 Japanese patients with hypertension who were treated with ARB/DU (n = 92) or ARB/CCB (n = 102) for 1 year. We examined change in blood pressure control as well as other clinical parameters. Correlations between change in blood pressure and clinical parameters were also determined. Results: After switching ARB/DU or ARB/CCB, systolic (SBP) and diastolic blood pressure (DBP) was significantly decreased in the both groups (Δ SBP: 8.1 and 8.5 mmHg and Δ DBP: 3.7 and 4.3 mmHg, respectively, all p < 0.01). Number of antihypertensives was significantly decreased after switching (3.0 ± 1.9 → 2.3 ± 1.4 tablets, p = 0.01 and 2.5 ± 1.6 → 1.3 ± 0.7 tablets, p < 0.01, respectively). There was a significant negative correlation between change in blood pressure after switching and blood pressure at baseline (p < 0.01). Conclusion: In clinical settings, use of fixed-dose combination tablets of ARB/DU and ARB/CCB significantly improved blood pressure control in Japanese patients with hypertension. Especially, switching to fixed-dose combination tablet should be considered in patients with poor blood pressure control.",
author = "Toshiki Wakabayashi and Yoshifumi Saisho and Toshihide Kawai and Kohichi Hayashi and Hiroshi Itoh",
year = "2013",
language = "English",
volume = "34",
pages = "1111--1118",
journal = "Therapeutic Research",
issn = "0289-8020",
publisher = "Life Science Publishing Co. Ltd",
number = "8",

}

TY - JOUR

T1 - Efficacy of fixed-dose combination tablets with candesartan 8 mg/hydrochlorothiazide 6.25 mg and candesartan 8 mg/amlodipine 5 mg in Japanese patients with hypertension

AU - Wakabayashi, Toshiki

AU - Saisho, Yoshifumi

AU - Kawai, Toshihide

AU - Hayashi, Kohichi

AU - Itoh, Hiroshi

PY - 2013

Y1 - 2013

N2 - Aims: To examine efficacy of fixed-dose combination tablets with candesartan 8 mg/hydrochlorothiazide 6.25 mg (ARB/DU) and candesartan 8 mg/amlodipine 5 mg (ARB/CCB) in Japanese patients with hypertension. Methods: We conducted a retrospective analysis of 201 Japanese patients with hypertension who were treated with ARB/DU (n = 92) or ARB/CCB (n = 102) for 1 year. We examined change in blood pressure control as well as other clinical parameters. Correlations between change in blood pressure and clinical parameters were also determined. Results: After switching ARB/DU or ARB/CCB, systolic (SBP) and diastolic blood pressure (DBP) was significantly decreased in the both groups (Δ SBP: 8.1 and 8.5 mmHg and Δ DBP: 3.7 and 4.3 mmHg, respectively, all p < 0.01). Number of antihypertensives was significantly decreased after switching (3.0 ± 1.9 → 2.3 ± 1.4 tablets, p = 0.01 and 2.5 ± 1.6 → 1.3 ± 0.7 tablets, p < 0.01, respectively). There was a significant negative correlation between change in blood pressure after switching and blood pressure at baseline (p < 0.01). Conclusion: In clinical settings, use of fixed-dose combination tablets of ARB/DU and ARB/CCB significantly improved blood pressure control in Japanese patients with hypertension. Especially, switching to fixed-dose combination tablet should be considered in patients with poor blood pressure control.

AB - Aims: To examine efficacy of fixed-dose combination tablets with candesartan 8 mg/hydrochlorothiazide 6.25 mg (ARB/DU) and candesartan 8 mg/amlodipine 5 mg (ARB/CCB) in Japanese patients with hypertension. Methods: We conducted a retrospective analysis of 201 Japanese patients with hypertension who were treated with ARB/DU (n = 92) or ARB/CCB (n = 102) for 1 year. We examined change in blood pressure control as well as other clinical parameters. Correlations between change in blood pressure and clinical parameters were also determined. Results: After switching ARB/DU or ARB/CCB, systolic (SBP) and diastolic blood pressure (DBP) was significantly decreased in the both groups (Δ SBP: 8.1 and 8.5 mmHg and Δ DBP: 3.7 and 4.3 mmHg, respectively, all p < 0.01). Number of antihypertensives was significantly decreased after switching (3.0 ± 1.9 → 2.3 ± 1.4 tablets, p = 0.01 and 2.5 ± 1.6 → 1.3 ± 0.7 tablets, p < 0.01, respectively). There was a significant negative correlation between change in blood pressure after switching and blood pressure at baseline (p < 0.01). Conclusion: In clinical settings, use of fixed-dose combination tablets of ARB/DU and ARB/CCB significantly improved blood pressure control in Japanese patients with hypertension. Especially, switching to fixed-dose combination tablet should be considered in patients with poor blood pressure control.

UR - http://www.scopus.com/inward/record.url?scp=84884345770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884345770&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84884345770

VL - 34

SP - 1111

EP - 1118

JO - Therapeutic Research

JF - Therapeutic Research

SN - 0289-8020

IS - 8

ER -